8-KItem 2.02 · Results of OperationsItem 9.01 · Financial Statements
Thermo Fisher reports 9% third-quarter revenue growth and higher EPS
Filed with the SEC on · Summarized by InvestorsBot
Thermo Fisher Scientific reported third-quarter 2026 revenue of $12.14 billion for the period ended September 26, up 9% year over year, including 6% organic growth; GAAP diluted EPS rose 9% to $4.64 and adjusted EPS increased 15% to $6.68. Operating margins improved, while nine-month free cash flow reached $4.62 billion, and the company completed its previously announced microbiology business divestiture; updated 2026 guidance was scheduled for its October 21 earnings call.